Drugs / H5 VLP Influenza vaccine
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT01244867 | Nov 2010 → Jul 2011 | respiratory tract infectious disorder, viral infectious disease | Medicago | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | H5 VLP Influenza vaccine | “20 µg, 30 µg or 45 µg H5 VLP Influenza vaccine combined with Alhydrogel®” NCT01244867 ↗ |
| Modality | Vaccine | “H5 VLP Influenza vaccine” NCT01244867 ↗ |